Q4 2024 Fagron NV Earnings Call Transcript
Key Points
- Fagron SA (XBRU:FAGR) reported a 13% organic revenue growth at constant exchange rates (CER), with a total revenue of EUR172 million.
- EBITDA grew by 16.8% year on year, with the margin improving to 20%, driven by global operational excellence initiatives.
- The company announced six acquisitions between the end of 2024 and early 2025, strengthening market positions and demonstrating financial discipline.
- Free cash flow conversion stood at 56.1%, adjusted for one-off CapEx and factoring, exceeding the midterm target of more than 50%.
- A proposed dividend of EUR0.35 per share represents a 17% increase compared to 2023, reflecting strong financial performance.
- The FDA issued a warning letter to Fagron SA (XBRU:FAGR) regarding its Wichita facility, with corrective actions still being implemented.
- Operating costs increased by 18.6% year on year, mainly due to growth in Compounding Services in North America and the impact of acquisitions.
- The effective tax rate increased to 22.3% from 15.9% due to a lower amount of net operating losses recognized in North America.
- The company faces temporary double costs due to the phased transition into the new Anazao facility in Tampa.
- The Brazilian real's depreciation negatively impacted financial results, affecting the LatAm region's reported growth.
Thank you, and good morning, everyone. Welcome to the full-year 2024 results webcast of Fagron. I'm here together with our CEO, Rafael Padilla, who will discuss the results and do a deep dive into the region's performance. And then our CFO, Karin de Jong, will go through the financials. Afterwards, they will open the call for your questions.
With that, I would like to hand over the call to Rafael.
Thank you, Ignacio, and welcome all. We're pleased to report our full-year financial results, which are in line with our guidance. Our revenue reached EUR172 million, translating into an impressive 13% organic revenue growth at CER. Growth was well balanced across all regions and segments with Compounding Services in North America being the primary driver.
Our EBITDA grew by 16.8% year on year with our margin improving to 20%, an increase of 50 basis points. This was mainly driven by the benefits of our global operational excellence initiatives. Free
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
